Lauren Cobb

Also affiliated with The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer”.

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

International Journal of Gynecological Cancer(2024)10.1136/ijgc-2024-005919

N/A

0.812DataRank · unranked

25 citations

Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Michel Fabbro, David M. O’Malley +16 more

Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer

International Journal of Gynecological Cancer(2020)10.1136/ijgc-2020-001718

N/A

0DataRank · unranked

8 citations

Shannon N. Westin, Larissa A. Meyer, Aaron Shafer, Jose Alejandro Rauh‐Hain, Michaela Onstad +12 more

Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.09.005

N/A

0DataRank · unranked

16 citations

Lauren Cobb, Shannon N. Westin, Yingao Zhang, Amir A. Jazaeri, Anaís Malpica +2 more

A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study

Cancer Epidemiology Biomarkers & Prevention(2022)10.1158/1055-9965.epi-22-0548

N/A

0DataRank · unranked

6 citations

Craig Messick, Andrea Milbourne, Ming Guo, Mark F. Munsell, Joël Fokom Domgue +14 more

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2819

N/A

0DataRank · unranked

12 citations

Yingao Zhang, Heather Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo +19 more

Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.08.024

N/A

0DataRank · unranked

3 citations

Thomas Welte, Veena K. Vuttaradhi, Xue Yang, Elio Tahan, Eleonora Khlebus +13 more

Repurposing Food and Drug Administration-approved cancer therapies: exploring endocrine and targeted pathways in low-grade serous ovarian cancer treatment

International Journal of Gynecological Cancer(2025)10.1016/j.ijgc.2025.101938

N/A

0DataRank · unranked

3 citations

Rachel N. Grisham, Robert L. Coleman, Lauren Cobb, Bradley J. Monk, Thomas J. Herzog +3 more

The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.06.498

N/A

0DataRank · unranked

53 citations

Charlotte C. Sun, Revathy B. Iyer, Alpa M. Nick, Nicole D. Fleming, Shannon N. Westin +5 more

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.02.015

N/A

0DataRank · unranked

2 citations

Rebecca A. Previs, Daniel Spinosa, Bryan Fellman, Amelia L. Scott, Isabelle Mulder +10 more